# Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas

> **NCT03786926** · PHASE1 · TERMINATED · sponsor: **Hutchmed** · enrollment: 53 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **DRUG:** HMPL-689

## Key facts

- **NCT ID:** NCT03786926
- **Lead sponsor:** Hutchmed
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-08-26
- **Primary completion:** 2024-06-26
- **Final completion:** 2024-06-26
- **Target enrollment:** 53 (ACTUAL)
- **Why stopped:** 2018-689-00US1 has been halted by HUTCHMED based on strategic evaluation of the clinical development of HMPL-689 in the United States, Europe, and Australia.
- **Last updated:** 2025-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03786926

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03786926, "Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT03786926. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*